

## Idogen - Q1 2023 – In a tough situation

Redeye comments on Idogen following the company's Q1 2023 report. The lack of financing has put the company in a rough spot, and it is working on a solution. However, liquidation seems to be the most likely scenario ahead.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

**Idogen - Q1 2023 – In a tough situation**